PharmAust Limited (PAA.AX)
AUD 0.23
(6.98%)
AUD 0.23
(6.98%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 896.6 Thousand AUD | -59.99% |
| 2023 | 2.24 Million AUD | 0.33% |
| 2022 | 2.23 Million AUD | 7.75% |
| 2021 | 2.07 Million AUD | -6.62% |
| 2020 | 2.22 Million AUD | 94.77% |
| 2019 | 1.13 Million AUD | -6.55% |
| 2018 | 1.21 Million AUD | -4.72% |
| 2017 | 1.28 Million AUD | 3.73% |
| 2016 | 1.23 Million AUD | 80.64% |
| 2015 | 683.21 Thousand AUD | 68.29% |
| 2014 | 405.98 Thousand AUD | -31.72% |
| 2013 | 594.54 Thousand AUD | -50.28% |
| 2012 | 1.19 Million AUD | 294.76% |
| 2011 | 302.94 Thousand AUD | -70.31% |
| 2010 | 1.02 Million AUD | -40.45% |
| 2009 | 1.71 Million AUD | -17.55% |
| 2008 | 2.07 Million AUD | -10.91% |
| 2007 | 2.33 Million AUD | 57.28% |
| 2006 | 1.48 Million AUD | 5.47% |
| 2005 | 1.4 Million AUD | 758.2% |
| 2004 | 163.86 Thousand AUD | -76.54% |
| 2003 | 698.49 Thousand AUD | -52.03% |
| 2002 | 1.45 Million AUD | 48.6% |
| 2001 | 979.8 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 896.6 Thousand AUD | 0.0% |
| 2024 Q2 | 1.22 Million AUD | 0.0% |
| 2024 FY | 896.6 Thousand AUD | -59.99% |
| 2023 Q4 | 2.24 Million AUD | 0.0% |
| 2023 FY | 2.24 Million AUD | 0.33% |
| 2023 Q2 | 2.3 Million AUD | 0.0% |
| 2022 Q2 | 2.24 Million AUD | 0.0% |
| 2022 Q4 | 2.23 Million AUD | 0.0% |
| 2022 FY | 2.23 Million AUD | 7.75% |
| 2021 FY | 2.07 Million AUD | -6.62% |
| 2021 Q4 | 2.07 Million AUD | 0.0% |
| 2021 Q2 | 2.25 Million AUD | 0.0% |
| 2020 Q4 | 2.22 Million AUD | 0.0% |
| 2020 Q2 | 2.24 Million AUD | 0.0% |
| 2020 FY | 2.22 Million AUD | 94.77% |
| 2019 Q4 | 1.13 Million AUD | 0.0% |
| 2019 Q2 | 1.17 Million AUD | 0.0% |
| 2019 FY | 1.13 Million AUD | -6.55% |
| 2018 FY | 1.21 Million AUD | -4.72% |
| 2018 Q4 | 1.21 Million AUD | 0.0% |
| 2018 Q2 | 1.26 Million AUD | 0.0% |
| 2017 Q2 | 1.25 Million AUD | 0.0% |
| 2017 FY | 1.28 Million AUD | 3.73% |
| 2017 Q4 | 1.28 Million AUD | 0.0% |
| 2016 Q4 | 1.23 Million AUD | 0.0% |
| 2016 Q2 | 1.33 Million AUD | 0.0% |
| 2016 FY | 1.23 Million AUD | 80.64% |
| 2015 Q2 | 428.09 Thousand AUD | 0.0% |
| 2015 Q4 | 683.21 Thousand AUD | 0.0% |
| 2015 FY | 683.21 Thousand AUD | 68.29% |
| 2014 Q1 | 474.64 Thousand AUD | -20.17% |
| 2014 Q2 | 474.64 Thousand AUD | 0.0% |
| 2014 Q4 | 445.47 Thousand AUD | 0.0% |
| 2014 FY | 405.98 Thousand AUD | -31.72% |
| 2013 Q1 | 935.31 Thousand AUD | -21.79% |
| 2013 FY | 594.54 Thousand AUD | -50.28% |
| 2013 Q4 | 594.54 Thousand AUD | 17.87% |
| 2013 Q3 | 504.41 Thousand AUD | -50.92% |
| 2013 Q2 | 1.02 Million AUD | 9.89% |
| 2012 FY | 1.19 Million AUD | 294.76% |
| 2012 Q4 | 1.19 Million AUD | 0.0% |
| 2011 Q4 | 302.94 Thousand AUD | 0.0% |
| 2011 FY | 302.94 Thousand AUD | -70.31% |
| 2010 Q4 | 1.02 Million AUD | 0.0% |
| 2010 FY | 1.02 Million AUD | -40.45% |
| 2009 Q4 | 1.71 Million AUD | 0.0% |
| 2009 FY | 1.71 Million AUD | -17.55% |
| 2008 FY | 2.07 Million AUD | -10.91% |
| 2008 Q4 | 2.07 Million AUD | 0.0% |
| 2007 Q4 | 2.33 Million AUD | 0.0% |
| 2007 FY | 2.33 Million AUD | 57.28% |
| 2006 Q4 | 1.48 Million AUD | 0.0% |
| 2006 FY | 1.48 Million AUD | 5.47% |
| 2005 Q4 | 1.4 Million AUD | 0.0% |
| 2005 FY | 1.4 Million AUD | 758.2% |
| 2004 FY | 163.86 Thousand AUD | -76.54% |
| 2004 Q4 | 163.86 Thousand AUD | 0.0% |
| 2003 Q4 | 698.49 Thousand AUD | 0.0% |
| 2003 FY | 698.49 Thousand AUD | -52.03% |
| 2002 Q4 | 1.45 Million AUD | 0.0% |
| 2002 FY | 1.45 Million AUD | 48.6% |
| 2001 FY | 979.8 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | 74.69% |
| Acrux Limited | 5.68 Million AUD | 84.234% |
| Actinogen Medical Limited | 1.61 Million AUD | 44.495% |
| AnteoTech Limited | 4.07 Million AUD | 77.999% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 63.053% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 56.404% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -192.198% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 83.475% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 73.835% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | 4.772% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -143.348% |
| Biome Australia Limited | 5.37 Million AUD | 83.314% |
| Biotron Limited | 737.5 Thousand AUD | -21.573% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 75.976% |
| BTC Health Limited | 203.94 Thousand AUD | -339.625% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 92.997% |
| CSL Limited | 27.88 Billion AUD | 99.997% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 89.239% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 96.811% |
| Cynata Therapeutics Limited | 1.17 Million AUD | 23.436% |
| Dimerix Limited | 13.89 Million AUD | 93.546% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 78.799% |
| Hexima Limited | 248.67 Thousand AUD | -260.561% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | 14.251% |
| Immuron Limited | 2.84 Million AUD | 68.435% |
| Immutep Limited | 10.97 Million AUD | 91.834% |
| Imugene Limited | 33.14 Million AUD | 97.295% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -107.726% |
| Memphasys Limited | 5.59 Million AUD | 83.967% |
| Nanollose Limited | 465.64 Thousand AUD | -92.552% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 97.903% |
| Noxopharm Limited | 1.28 Million AUD | 30.421% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -946.423% |
| Nyrada Inc. | 855.63 Thousand AUD | -4.789% |
| Orthocell Limited | 22.08 Million AUD | 95.94% |
| Patrys Limited | 691.36 Thousand AUD | -29.686% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 74.985% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | 44.856% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 61.446% |
| PYC Therapeutics Limited | 10.18 Million AUD | 91.196% |
| Race Oncology Limited | 1.91 Million AUD | 53.215% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 97.993% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 94.359% |
| Starpharma Holdings Limited | 8.69 Million AUD | 89.692% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.64% |
| Tissue Repair Ltd | 1.35 Million AUD | 33.629% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 90.417% |